Founder, Chief Executive Officer
Celia has 15 year’s experience in the pharmaceutical industry. As the global head of clinical trial logistics and supply chain in Sanofi R&D, Celia was a permanent member of the clinical strategic committees and reviewer of clinical plans and study protocols. In that role, she conducted clinical trials in Oncology, Neurology and Psychiatry, among others. She also has considerable experience in driving and implementing structural and organizational changes with agility and in alignment with company strategies.
Before co-founding CILcare, Celia was the Director of projects dealing with major chronic diseases associated with aging. It was in the course of this work that she developed her interest and expertise in hearing disorders (and her sensitivity to this particular domain, as she has been a singer in many rock and jazz bands since she was 10). In addition, she led projects for consumer health care in T2 diabetes and age-related hearing loss, and contributed to the set-up of collaborative programs with giant food companies for direct-to-consumer markets.
She benefited from various leader programs for talent management and was trained at ESSEC and London Business Schools in addition to several masters degrees in project management, industrial strategy and health environment.
Founder, Chief Scientific Officer
Dr. Cosnier-Pucheu has more than 23 years’ experience in academic research and the pharmaceutical industry. Before co-founding CILcare, Sylvie headed up an in-vivo pharmacology group working on tinnitus and hearing loss. In the course of this work, she collaborated with a number of highly-regarded academic experts in Hearing Disorders, who are now mentoring the CILcare laboratory team.
In addition, Sylvie led scientific teams and developed animal models, mainly in rodents, to support drug discovery and development at Sanofi in the fields of cardiology, oncology, aging and hearing. She also has extensive experience in approaches related to the antioxidant mechanisms, which are part of the investigated pathways in the hearing field. She has always been deeply involved in Animal Well-being and was part of the Ethics Committee of Sanofi for years.
Sylvie has a Ph.D in cardiovascular pharmacology from the University of Grenoble. She performed a post-doc in Boston for the company Eukarion and has a degree in clinical development. She is the author of several publications and of a patent.
Founder, Chief Development Officer
Dr. Pasdelou has more than 24 years of experience in the pharmaceutical industry, mainly as a drug developer. Over the last 12 years, Marie-Pierre led both transversal information management projects and drug development projects. She was Director for the development of 5 products in the area of antithrombotics before moving to a strategic therapeutic unit dedicated to Aging, where she began to develop her interest and expertise in hearing disorders.
Marie-Pierre has outstanding experience driving multi-disciplinary and multi-cultural teams in all phases of drug development, from entry into the preclinical stage to the filing of market authorization dossiers and beyond, having started her career by leading an International Regulatory Department at Sanofi in charge of the preparation of files for worldwide submission and the review of preclinical dossiers. She is also an expert in public health, integrated solutions and mobile health.
Marie- Pierre received a Pharm.D from Paris V and has degrees in Pharmacokinetics and Geron-technology.
Laboratory Manager and Engineer
Philippe has more than 10 years’ experience in in vivo pharmacology and small animal imaging, with a strong pharmaceutical industry background. He is highly regarded for the quality and precision of his work in animal research, and maintains continuing relationships with several international experts in tinnitus and hearing loss to ensure he keeps his technical skills current.
Prior to joining CILcare, Philippe studied and developed animal models in several therapeutic axes at Sanofi, including cardiovascular, oncology and hearing deficiencies.
Philippe has an engineering degree in Life Sciences and Pharmacology, and is the author of reports on tinnitus drug development.
Engineer, R&D Project Manager and IMPLAN-T Project Director
Aurore specializes in in-vivo Pharmacology. Her key competencies in the laboratory include electro-physiological measurements and brain surgery. Before joining CILcare, she was working in Neuroscience, testing drug candidates on behavioral models of cognitive impairment.
Aurore is particularly talented in complex surgical procedures used in CILcare’s pharmacological models to measure evoked potentials of the auditory function on chronic and acute protocols. She developed several protocols of noise-induction, which are used in CILcare’s models of noise-induced hearing disorders representing one of CILcare’s key know-hows. In addition to her excellent laboratory skills, she is particularly knowledgeable in project management and drives IMPLAN-T, a collaborative project aiming to accelerate the development of an intra-cochlear drug delivery system.
Aurore graduated with honors in Project Management and Innovation in Biotechnology from the University of Montpellier.
R&D Project Manager and COCHEOFIX Project Director
Dr. Malmström has more than 12 years’ experience in academic research and in the preclinical pharmaceutic CRO-business. Before joining CILcare, she spent five years working with rodent models and biomarker validation in the area of neurodegenerative diseases. She is expert in managing research and development projects, with a broad in vitro- and in vivo technical competence.
She coordinates and drives the pharmacokinetic studies at CILcare and as such, she interacts with international experts of the field, who she involves in the continuous improvement of CILcare’s protocols. In addition, she drives Cochleofix, one of CILcare’s key collaborative projects with KeenEye and the contribution of the Institut Pasteur.
Susanna holds a Ph. D in biochemistry and molecular biology from the University of Lund, Sweden, in the field of ion transport. She obtained her M.A. from the University of Texas in Austin and conducted part of her thesis work in Copenhagen, Denmark. She is the author of several scientific publications.
Engineer, R&D Project Manager
Veronique’s expertise is in the most advanced electrophysiological and electroacoustic measurement techniques. She worked in the laboratory of Professor Paul Avan, who is known world-wide for the measurements of Evoked Potentials.
Veronique focuses on the development and management of behavioral models for the tinnitus platform, and in the continuous improvement of CILcare’s laboratories.
She holds a master’s degree in Pharmaceutical Sciences from the University of Clermont Ferrand.
Chief Operations Officer
Dr. Naert’s keen interest in understanding complex mechanisms has taken her through several aspects of research and project development. She spent 13 years in France and Canada developing animal models to investigate the therapeutic avenues of major Central Nervous System (CNS) disorders, such as depression and Alzheimer’s disease, also related, as otic and hearing diseases are, to neuro-inflammation processes.
Before joining CILcare, Gaëlle worked in a company dedicated to developing drugs for CNS disorders. In addition to her excellent scientific skills, Gaëlle, who comes from a family of entrepreneurs, has a wide range of project management and business development competencies. She has written many scientific communications and publications, and has received many scholarships and awards. She holds a Ph.D in Cellular and molecular endocrinology from the University of Montpellier.
R&D Project Manager and DETEC-T Project Director
Dr. Gonzalez has strong technical competence in animal surgery, in vivo imaging, electrophysiology and behavioral tests, and solid experience in managing research and development projects. Before joining CILcare, he worked for three years in the molecular and cellular mechanism of peripheral nervous system degeneration and regeneration, and taught Cellular Biology and Biochemistry in the University of Montpellier and Barcelona.
Sergio holds a Ph. D in biochemistry and molecular biology from the University of Barcelona, Spain, in the field of neuronal receptors and neurodegenerative diseases. He performed a post-doc at the Institute for Neurosciences of Montpellier, and received a certificate in Rodent Experimental Surgery at Montpellier University, France. He is the author of several international publications and holds a patent.
Associate Director Marketing & Business Development
Marie brings a broad range of innovation marketing and business development experience. She is responsible for the strategic direction of commercial activities for CILcare, including marketing, business development, and communication.
Prior to CILcare, she created and led the marketing strategy globally in a start-up specializing in the development and marketing of health food ingredients for Type 2 diabetes prevention. In addition, she also served as Clinical Project Manager and managed the conduct of clinical trials, in partnership with CRO’s, from protocol design to publications.
Across her various professional experience, she played key roles in product launches in pharma, nutraceutical and cosmetic industries. Marie is a biochemical engineer and received a degree in innovation marketing from Toulouse Business School.